Covid 19 Research using Clinical Trials (Home Page)
HP:0000405: Conductive hearing impairmentHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated MeSH Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003638 | Deafness NIH | 1.00 |
| D010034 | Otitis Media with Effusion NIH | 1.00 |
| D034381 | Hearing Loss NIH | 1.00 |
| D006314 | Hearing Loss, Conductive NIH | 1.00 |
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0040262 | Glue ear HPO | 1.00 |
| HP:0000365 | Hearing impairment HPO | 0.71 |
There is one clinical trial.
Clinical Trials
1 Exploring Interventions for Children With Chronic Otitis Media With Effusion ('Glue Ear') When Services Are Reduced During Covid-19
During the Coronavirus pandemic children's hearing services are closed or reduced and grommet operations are part of the lowest priority group. In the absence of management options, this research study aims to see if bone conduction headphones either paired (via bluetooth) to a microphone or an app will help children with a hearing loss during this period of waiting. The child's quality of life is measured with validated questionnaires The study is over 3 months, and delivered remotely, with the product being sent to the family home and support offered via telephone/ video consulattion.
NCT04427631 Hearing Impaired Children Glue Ear Hearing Loss, Conductive Device: Bone conduction headphones MeSH:Hearing Loss Deafness Otitis Media with Effusion Hearing Loss, Conductive
HPO:Conductive hearing impairment Glue ear Hearing impairment
Primary Outcomes
Description: questionnaire based accpetability question. A higher acceptability score will be positive for the intervention.
Measure: acceptability of management strategy, questionnaire Time: Acceptability will be measured on a Likert scale pre-assessment and the end of 3 months of using the intervention
Secondary Outcomes
Description: validated questionnaire assessing quality of life in children with glue ear. The questionnaire assess disease- related hearing difficulty and treatment-related improvements in hearing. Improved (lower) scores will indicate a more positive response from the intervention.
Measure: quality of life questionnaire OMQ-14 Time: Questionnaires at beginning of study (as a baseline assessment and after 3 months of using the intervention. The sc
HPO Nodes
HP:0000405: Conductive hearing impairment
Genes 393
TWIST1 RSPH1 CTBP1 SPAG1 ELMO2 KCNAB2 RPS28 TCOF1 AFF4 REEP6 PRPF6 FGFR2 KIAA1549 AMMECR1 DNAH1 MAP3K7 NF1 FGFR2 PORCN SIX1 DNAAF1 CHRNG NSD1 FGFRL1 CHD7 GSC DNAH9 RDH12 SALL4 ZNF408 RSPH4A BPTF GAS8 TELO2 GJA1 CCDC65 DCHS1 COL2A1 POLR1D SIX1 RAI1 TFAP2A FGFR3 SEMA3E GJB2 EYA1 SLC7A14 EDNRA NEK1 MAN2B1 MAP3K7 AGBL5 FRAS1 CHRNG KMT2D FAM20C SDHA SNRPB SKI RAD21 DHODH ARVCF BEST1 CRX HOXA2 COL2A1 MASP1 FANCI EXT1 IQSEC2 SKI RBP3 CNGB1 RAB23 NECTIN1 ZNF513 SLC25A11 CREB3L1 DNAAF6 B3GLCT CPLANE1 IFT140 CCDC103 POLR1C DNAAF4 TNFRSF11A MEOX1 OFD1 ANKH GJB6 SMC1A ARL6 UFD1 LETM1 CDHR1 CTNND1 MYH3 FGFR3 SDHD RET CNGA1 DHDDS PSMD12 FLNB FOXJ1 NOTCH3 DLST GJA1 KIZ GAS8 PRPF8 POU3F4 ALX3 DNAL1 NSD2 NEK2 ANKH DEAF1 MAK ALX3 BBS2 COMT POR FGFR2 RSPH9 SLITRK6 JMJD1C ERF TP63 EFTUD2 DCHS1 ACVR1 ABCA4 C8ORF37 PCGF2 HIRA SIX1 CERKL NRL PAX1 CPLX1 DVL1 POLR1C COL1A2 PROM1 FGFR3 SDHB DNAI1 MDH2 EYA1 IMPDH1 DNAJB13 CDH11 DNMT3A PRCD SLC25A24 FKBP14 FAT4 PRPF4 CA4 TUB TCTN3 TTC8 NSD1 NR2E3 TBX1 CCBE1 CDH1 KMT2A PCARE LRRC6 RPS26 TRPS1 DNAAF5 CCNO RET NOG HDAC4 SPECC1L SEC24C NOG POU3F4 HGSNAT ALX1 LRRC56 FAT4 EYA1 DLX4 GRHL3 FGFR2 NOG ARHGEF18 RP1 DNAAF3 CLRN1 AHR HDAC8 NOG PDE6D AMER1 OSTM1 MSX1 PRDM5 MCIDAS SDHB SDHAF2 VHL TCTN3 RECQL4 ZBTB20 CDH1 GUCA1B PDE6G SRCAP TFAP2A FGF9 CPLANE1 CFAP221 AMER1 NIPBL RAI1 PRDM16 RPGR TOPORS STK36 IDH3B GMNN SCAPER COL11A2 OFD1 SDHD ARL2BP SDHD EYA1 FLNA TXNL4A TSR2 RREB1 NME8 PDE6B FRAS1 SDHC FH LONP1 BMP2 NECTIN1 CFAP298 CNOT1 MAN2B1 CFAP300 PRPF3 SMC3 SPATA7 TP63 SPEF2 NIPBL ZNF469 RERE ZMYND10 TSHZ1 MAP3K7 GJA1 RECQL4 FREM2 DHODH CCDC39 ARMC4 GJA1 PRRX1 RPGR APC2 EYA1 DNAI2 NEK10 EPAS1 DNAI1 PTPN22 CCBE1 AHI1 EDN1 TP63 SAG FGFR2 FGF10 TP63 GP1BB SOST CFAP300 DLG1 ARHGAP29 EFTUD2 EYS FAM149B1 LRP5 GATA1 SC5D RGR GAS2L2 CCDC151 DHX38 IDH3A TNFRSF11A GDF5 GNPTAB FGFR3 RHO PIGL POLR1D RP9 TMEM67 SF3B4 KLHL7 KIF7 STAC3 TCOF1 RPS23 KIAA0753 RLBP1 TBX22 DNAH5 NFIX ADAMTS3 CDCA7 TTC12 SLC25A24 ANKRD11 GRIP1 PGM3 TBX1 TMEM127 USH2A FLII RP2 SETD5 MAP3K7 IFT172 CCDC40 PAX1 FAM161A WHCR RPE65 PRPH2 ROM1 IRF6 FLNA TMEM216 UBB FLNB TTC25 DNAAF2 SEMA4A ARL3 GDF6 BMP4 NOTCH2 LRAT MAX GABRD DRC1 TULP1 SNRNP200 IFT88 KIF1B MSX1 SGMS2 RSPH3 FSCN2 MERTK OFD1 COL2A1 HYDIN FBN1 NOTCH3 IMPG2 POMGNT1 CCDC114 SKI STAC3 PRPF31 KDM6A SNRPB SETD2 FLNB FAT4 VHL PDE6A PGM3 IRF6 CRB1 ARID2 FLNA COL2A1 DNAH11 Protein Mutations 0
SNP 0
Primary Outcomes
Description: questionnaire based accpetability question. A higher acceptability score will be positive for the intervention.
Measure: acceptability of management strategy, questionnaire Time: Acceptability will be measured on a Likert scale pre-assessment and the end of 3 months of using the interventionSecondary Outcomes
Description: validated questionnaire assessing quality of life in children with glue ear. The questionnaire assess disease- related hearing difficulty and treatment-related improvements in hearing. Improved (lower) scores will indicate a more positive response from the intervention.
Measure: quality of life questionnaire OMQ-14 Time: Questionnaires at beginning of study (as a baseline assessment and after 3 months of using the intervention. The sc